{"filings":[{"id":843316,"accession_number":"0001665988-26-000035","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-06-04T11:54:06+00:00","items":["5.07"],"status":"ready","headline":"Bioventus stockholders elect all 12 director nominees and ratify Grant Thornton as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 director nominees elected; votes-for ranged from 61.7M (Sutter) to 68.5M (Dhankhar).","Stockholders ratified Grant Thornton LLP as independent auditor for FY 2026 with 75.2M votes in favor.","Approximately 90.23% of outstanding shares (75.3M shares) were represented at the meeting.","Director Martin P. Sutter received 6.8M withheld votes, more than any other nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":583876,"accession_number":"0001665988-26-000029","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-05-21T20:58:18+00:00","items":["7.01"],"status":"ready","headline":"Bioventus Exogen device reclassified by FDA, CMS updates reimbursement rates; company reiterates 2026 guidance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA reclassified non-invasive bone growth stimulators, including Bioventus' Exogen Ultrasound Bone Healing System, from Class III to Class II on April 16, 2026.","CMS updated Medicare fee schedule for HCPCS codes E0747, E0748, and E0760 for services on or after May 18, 2026.","Bioventus does not expect material impact from reimbursement rate changes on its FY2026 financial results.","Company reiterates previously issued 2026 financial guidance despite the regulatory changes.","Bioventus continues to evaluate long-term impact; future CMS actions could require revised outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94529,"accession_number":"0001665988-26-000026","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue up 7% to $132.1M; GAAP EPS $0.04, raises FY26 EPS and CFO guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $132.1M (+7% YoY); GAAP EPS $0.04 vs -$0.04; Non-GAAP EPS $0.15 vs $0.08 (+88%).","Adjusted EBITDA $23.9M (+24% from $19.2M); cash from ops $8.9M vs -$19.3M.","Pain Treatments +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%; International +17.1%.","Raised FY26 Adj EPS guidance to $0.75-$0.79 (up $0.02), CFO to $84-$89M (up $2M); reaffirms rev $600-610M.","Discretionary $22M term loan prepayment on Mar 27 reduces debt and future interest."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":132089000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106978,"accession_number":"0001665988-26-000010","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 GAAP EPS $0.21, revenue $157.9M; guides FY2026 sales $600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $157.9M (+2.8% reported, +10.0% organic); GAAP EPS $0.21 (vs $0.00); non-GAAP EPS $0.24; Adj. EBITDA $36.7M (+30%).","Full year 2025 revenue $568.1M (-0.9% reported, +7.5% organic); GAAP EPS $0.33 (vs -$0.56); Adj. EPS $0.68 (+21.4%).","FY2026 guidance: net sales $600-610M (6-7% growth); Adj. EPS $0.73-$0.77 (7-13% growth); cash from ops $82-87M.","Q4 cash from operations $38M (+97% YoY); full year cash from ops up 92%; debt reduced by $29M in Q4.","Launched PNS products StimTrial and TalisMann; added Megan Rosengarten as SVP/GM PNS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123318,"accession_number":"0001665988-25-000032","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioventus appoints Ajay Dhankhar to board as Smith & Nephew designee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective November 14, 2025; Dhankhar serves as Class II director until 2026 annual meeting.","Dhankhar is Chief Corporate Development & Strategy Officer at Smith & Nephew (SNN) since June 2025.","He is the second designee from S+N stockholders under the Stockholders Agreement.","Dhankhar will not receive any compensation from Bioventus for board service.","No family relationships or material interests in any transaction with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123317,"accession_number":"0001665988-25-000025","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q3 GAAP EPS $0.05 vs -$0.08 YoY; organic revenue +8% to $138.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.2M vs $5.2M loss; diluted EPS $0.05 improved from -$0.08 YoY.","Non-GAAP EPS $0.15, up 200% from $0.05; Adjusted EBITDA $26.6M (+12.9%) with margin 19.2%.","Organic revenue growth 8.2% led by Pain Treatments (+6.4%) and Surgical Solutions (+9.3%).","Cash from operations $30.1M, +192% YoY; reaffirms FY2025 revenue $560-570M and Adj. EBITDA $112-116M.","Entered new credit agreement with $300M term loan and $100M revolver, reducing annual interest by ~$2M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":410187000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139987,"accession_number":"0001665988-25-000016","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 organic revenue up 6.2%; EPS $0.11 vs loss; reaffirms FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $147.7M (-2.4% reported); organic revenue +6.2%, driven by double-digit growth in Surgical Solutions and Restorative Therapies.","Diluted EPS $0.11 vs loss of $0.40; non-GAAP EPS $0.21, up 31% YoY on lower interest and equity compensation.","Adjusted EBITDA $33.8M vs $34.5M; cash from operations $25.9M, up 71%.","Reaffirmed FY2025 guidance: revenue $560-570M, Adjusted EBITDA $112-116M, non-GAAP EPS $0.64-0.68.","Received FDA 510(k) clearance for TalisMann and StimTrial PNS systems in July 2025, addressing chronic nerve pain."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":271536000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139986,"accession_number":"0001193125-25-172192","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Bioventus enters $400M credit facility to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M revolving credit facility and $300M term loan A facility, maturing July 31, 2030.","Initial interest rate: Term SOFR + 2.50% margin, subject to performance grid (1.75%-2.75%).","$30M drawn on revolver at closing; proceeds used to refinance existing 2019 credit facilities.","Financial covenants: max total net leverage ratio 4.00x (step down to 3.50x), min interest coverage 2.50x.","Facility secured by substantially all assets; includes $7.5M L/C and $7.5M swingline subfacilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139985,"accession_number":"0001665988-25-000013","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioventus receives FDA 510(k) clearances for TalisMann and StimTrial PNS products","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted 510(k) clearance for TalisMann PNS system with integrated pulse generator for deeper/larger nerves.","StimTrial is a trial lead to evaluate patient response, expected to aid physician adoption and payer reimbursement.","Limited commercial release in select U.S. markets in Q3 2025; broader rollout planned for early 2026.","PNS market growing >20% annually, expected to exceed $500M by 2029, representing a growth opportunity.","Company offers comprehensive PNS portfolio for chronic pain management with non-opioid, minimally invasive therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157602,"accession_number":"0001665988-25-000010","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bioventus shareholders elect all six director nominees, ratify Grant Thornton as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six Class I director nominees elected with 58M to 64.9M votes; broker non-votes 8.59M each.","Ratification of Grant Thornton as auditor: 73.46M for, 149k against, 11k abstain.","Turnout: 73.62M shares (89.76% of outstanding) present at June 3, 2025 annual meeting.","Directors elected until 2026 annual meeting: Claypoole, Cowdy, McMurry-Heath, Neels, Nohra, Sutter.","No other business voted on; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157601,"accession_number":"0001628280-25-022400","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue $123.9M, organic +5%; Non-GAAP EPS $0.08, up 33% YoY, guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $123.9M, reported -4.3% but organic +5.0%; GAAP net loss $0.04/share vs $0.08 prior.","Non-GAAP EPS $0.08, up 33% YoY; Adjusted EBITDA $19.2M vs $22.6M prior due to divestiture.","Pain Treatments +3.9%, Surgical Solutions +7.0%, Restorative Therapies -35.3% (reflecting rehab divestiture).","FY2025 guidance reaffirmed: revenue $560-570M, Adj. EBITDA $112-116M, Non-GAAP EPS $0.64-0.68.","Entered distribution agreement for XCELL PRP system; added new senior leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":123876000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175977,"accession_number":"0001628280-25-011830","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 revenue $153.6M (+13.5%); FY2025 guidance implies 6-8% organic growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss from cont ops $0.3M vs ($7.7M) prior year; adj EBITDA $28.3M (+28.3%).","FY2024 revenue $573.3M (+11.9%); net loss $43.8M vs ($121.2M); adj EBITDA $108.9M (+22.5%).","FY2025 guidance: net sales $560-570M, adj EBITDA $112-116M, non-GAAP EPS $0.64-$0.68.","Debt reduced by $48.3M in Q4; Advanced Rehabilitation Business divested for $24.7M proceeds.","Pain Treatments and Surgical Solutions each delivered double-digit revenue growth for fifth straight quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175976,"accession_number":"0001628280-25-000253","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Bioventus completes divestiture of Advanced Rehab business to Accelmed for $25M cash plus $20M earn-out","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Closed sale of Advanced Rehabilitation business to Accelmed Partners on Dec 31, 2024.","Received $25M cash at closing, subject to working capital adjustments.","Up to $20M in earn-out payments based on 2025-2026 revenue and EBITDA thresholds.","Net closing proceeds of approx $20M to enhance liquidity; company to focus on core businesses.","Accelmed is a private equity firm focused on commercial-stage HealthTech companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192894,"accession_number":"0001628280-24-045112","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q3 revenue up 15% to $139M; raises FY2024 guidance midpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $139.0M (+15.0% YoY); net loss improved to $5.4M from $8.8M; Adjusted EBITDA $23.6M (+8.4%).","Non-GAAP EPS $0.06 vs $0.05; GAAP loss per share $0.07 vs $0.12.","Pain Treatments +16.7%, Surgical Solutions +18.5%, Restorative Therapies +1.2% (all YoY).","Agreed to divest Advanced Rehabilitation Business for up to $45M; close expected late 2024/early 2025; proceeds to reduce debt.","FY2024 guidance: net sales $562-567M, Adj. EBITDA $104-107M, Non-GAAP EPS $0.40-0.42 (midpoints raised)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":419638000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192893,"accession_number":"0001628280-24-042266","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioventus divests Advanced Rehabilitation business to Accelmed for up to $45M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total cash consideration of $45M: $25M at close plus up to $20M in earn-outs.","Net proceeds of ~$20M after fees and expenses will be used to repay existing debt.","Divestiture reduces annual revenue by ~$50M and annual Adj. EBITDA by ~$6M.","Transaction expected to close in Q4 2024, subject to customary conditions.","Bioventus to focus on core business and improve liquidity with the sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209291,"accession_number":"0001628280-24-034976","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q2 revenue up 10.3% (organic +13.9%); raises FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.2M (+10.3% YoY); Pain Treatments +17.2%, Surgical Solutions +18.6% US.","Net loss from continuing operations $32.1M vs $4.7M, including $31.9M impairment and litigation settlement.","Adjusted EBITDA $34.5M (+22.4% YoY); non-GAAP EPS $0.19 vs $0.14.","Raising FY2024 guidance: revenue $557-567M, adjusted EBITDA $104-107M, non-GAAP EPS $0.36-0.42.","FDA clearance for OSTEOAMP Cannula; pursuing divestiture of Advanced Rehabilitation to reduce debt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":280674000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209290,"accession_number":"0001193125-24-181655","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bioventus settles securities class action for $15.25M; insurers to cover ~$6.5M","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement amount $15.25M plus interest, subject to court approval; all claims against Bioventus and defendants dismissed.","Insurers expected to pay approximately $6.5M of the settlement; no admission of liability or wrongdoing by any party.","Lawsuit alleged failure to disclose rebate practices, financial prospects, and internal controls; Exchange Act claims survived motion to dismiss.","Settlement reached July 15, 2024; payment due within 30 days after court preliminary approval and receipt of transfer info."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227252,"accession_number":"0001193125-24-165735","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bioventus amends stockholders agreement to phase out classified board structure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Stockholders Agreement moves to annual director elections after 2024 annual meeting.","Existing three-year terms for current directors continue until expiration; successors will serve one-year terms.","Company authorized to amend charter and bylaws to reflect declassification of the Board.","Change applies to director designees of Essex and S+N principal stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227251,"accession_number":"0001193125-24-162669","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Bioventus stockholders approve board declassification, annual director elections by 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Declassification Charter Amendment approved: 61,439,110 for, 135,200 against, 22,572 abstain.","Board will shift to annual elections; entire board elected yearly starting 2026 annual meeting.","Class III directors elected: Robert E. Claypoole, Philip G. Cowdy, Martin P. Sutter.","Ratification of Grant Thornton as auditor for FY 2024: 71,179,096 for, 14,660 against.","Amendment effective upon filing certificate of amendment with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227250,"accession_number":"0001628280-24-020843","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.","Pain Treatments revenue $56.7M (+23.5% US); Surgical Solutions revenue $42.3M (+19.0% US).","Adjusted EBITDA $22.6M, up 33.5% YoY; adjusted gross margin expanded 190 bps.","FY 2024 guidance raised: net sales $535-550M, Adj. EBITDA $94-99M, Non-GAAP EPS $0.25-0.33.","Organic revenue growth 15.3% driven by Pain Treatments and Surgical Solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":129457000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246139,"accession_number":"0001628280-24-010371","cik":1665988,"company_name":"Bioventus Inc.","ticker":"BVS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bioventus Q4 revenue up 7.6% to $135.4M; guides FY2024 sales $520-535M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $135.4M (+7.6% reported; +14.3% organic); Pain Treatments grew >20%.","Net loss from continuing ops $7.7M vs $35.4M prior year; adjusted EBITDA $22.0M (+28.1%).","Full year 2023 revenue $512.3M (flat YoY); net loss $121.2M vs $144.7M; adj. EBITDA $88.9M (+29.5%).","Appointed Rob Claypoole as President and CEO, effective prior to Q4 close.","FY2024 guidance: net sales $520-535M, adjusted EBITDA $89-94M, non-GAAP EPS $0.12-$0.20."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":730093980.1460675,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}